Abcam’s aim is to serve life science researchers to achieve their mission, faster. We continuously listen, collaborate and support the scientific community in order to improve and offer new affinity binders, reagents, biomarkers and assays that will drive greater scientific progress.
Our culture is a key differentiator. We believe in empowering individuals, with responsibility given at an early stage. The working environment is fun and fast-paced, collaborative and outcome focused, with a strong customer focus. In addition to competitive salaries we offer an attractive flexible benefits package with plenty of opportunities to learn and grow.
Our head office is in Cambridge (UK), we also have offices in Bristol (UK), Cambridge, Eugene and San Francisco (USA), Tokyo (Japan), Hong Kong, Hangzhou and Shanghai (China).
We have a range of roles in IT background and would normally look for candidates with a degree in computer science or other numerate disciplines. We also recruit positions for candidates with a scientific background and we would normally look for candidates with biological science qualifications.
Show moreAbcam was founded in 1998 and is headquartered in Milton, GB
Report incorrect company information
Key People/Management at Abcam
Jonathan Milner
CEO
Report incorrect company information
Abcam Office Locations
Abcam has offices in San Francisco, Eugene, Tokyo, Milton and in 8 other locations
Milton, GB (HQ)
330 Cambridge Science Park Milton Rd
Cambridge, US (HQ)
b2304 One Kendall Square Binney St
Shanghai, CN
Galileo Rd. Pudong
Tokyo, JP
2-2-1 Nihonbashi Horidome-cho
Cambridge, US
b2304 1 Kendall Square
Report incorrect company information
Abcam Financials and Metrics
Abcam Revenue
Abcam's revenue was reported to be £217.10 m in FY, 2017
| GBP | |
|---|---|
Revenue (FY, 2017) | 217.1 m |
Gross profit (FY, 2017) | 152.1 m |
Gross profit margin (FY, 2017), % | 70.1% |
Net income (FY, 2017) | 42.4 m |
EBITDA (FY, 2017) | 70.5 m |
EBIT (FY, 2017) | 55.1 m |
Cash (30-Jun-2017) | 84.8 m |
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 248.4 k | 719.6 k | 1.8 m | 3.5 m | 6.7 m | 12.1 m | 19.4 m | 24.5 m | 36.7 m | 56.8 m | 71.1 m | 83.3 m | 97.8 m | 122.2 m | 128 m | 144 m | 171.7 m | 217.1 m |
Revenue growth, % | 13% | 19% | ||||||||||||||||
Cost of goods sold | 160.4 k | 416.1 k | 820.6 k | 1.4 m | 2.5 m | 4.7 m | 7.5 m | 10 m | 14.4 m | 19.4 m | 23.7 m | 27.2 m | 30.3 m | 35.5 m | 37.6 m | 42.5 m | 51.1 m | 65 m |
Gross profit | 88 k | 303.5 k | 983.7 k | 2.1 m | 4.2 m | 7.5 m | 11.9 m | 14.5 m | 22.3 m | 37.4 m | 47.4 m | 56 m | 67.6 m | 86.7 m | 90.4 m | 101.5 m | 120.5 m | 152.1 m |
| GBP | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 9.6 k | 269.1 k | 87.3 k | 59.1 k | 66.1 k | 274.3 k | 510 k | 884 k | 2.2 m | 13.5 m | 25.5 m | 40.2 m | 55.6 m | 14 m | 37.3 m | 55.3 m | 57.1 m | 68.9 m | 84.8 m |
Accounts Receivable | 55.1 k | 158.6 k | 261 k | 424.8 k | 926.8 k | 1.7 m | 2.4 m | 3.3 m | 3.7 m | 5.4 m | 6.8 m | 7.9 m | 11.5 m | 12.1 m | 13.2 m | 19.6 m | |||
Inventories | 3.2 k | 4 k | 18.1 k | 69.4 k | 185.9 k | 557.8 k | 1.2 m | 2.4 m | 3.1 m | 4.5 m | 6.8 m | 9.1 m | 10.7 m | 15.4 m | 15.3 m | 14.8 m | 19.8 m | 19.7 m | 21.8 m |
Current Assets | 33.6 k | 362.3 k | 320.8 k | 696.5 k | 864.3 k | 2.7 m | 4.6 m | 17 m | 18.1 m | 23.9 m | 40.1 m | 58.5 m | 76.4 m | 48.7 m | 71.3 m | 90.9 m | 100.5 m | 119.7 m | 143.5 m |
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (190.1 k) | (471.9 k) | (328.2 k) | 517.2 k | 1 m | 2.3 m | 3.7 m | 4.1 m | 5.9 m | 12.3 m | 19.2 m | 23.8 m | 25.4 m | 32.7 m | 34 m | 37.4 m | 37.4 m | 42.4 m |
Cash From Operating Activities | 2.6 m | 3.5 m | 4.9 m | 7.1 m | 14.8 m | 19.7 m | 25.5 m | 24.5 m | 39.4 m | 41.3 m | 40.2 m | 47.3 m | 66.4 m | |||||
Dividends Paid | 300 k | 1.3 m | 1.2 m | 968 k | 2.6 m | 5.3 m | 7.9 m | 10.1 m | 12.5 m | 11.3 m | 15.9 m | 16.7 m | 19.1 m | |||||
Cash From Financing Activities | 570 k | 9.3 m | 47 k | (2.2 m) | (1.2 m) | (27.4 m) | (7.6 m) | 10.7 m | (11.8 m) | (13.8 m) | (14.1 m) | (15.4 m) | (17.7 m) |
| GBP | Y, 2017 |
|---|---|
Revenue/Employee | 237.3 k |
Financial Leverage | 1.2 x |
Report incorrect company information
Abcam Online and Social Media Presence
5.16k Twitter followers
Abcam has 5.16k Twitter Followers. The number of followers has increased 1.9% month over month and increased 5.3% quarter over quarter
10.21k Facebook likes
Abcam has 10.21k Facebook Likes. The number of likes has increased 4.7% month over month and increased 20.2% quarter over quarter
Report incorrect company information
Abcam News and Updates
July 23, 2018
Alpha-lactalbumin Market : Industry Perspective and Comprehensive Analysis 2024
Persistence Market Research has announced the addition of the “Alpha-lactalbumin Market: Global Industry Analysis and Opportunity Assessment 2016 - 2024" report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday
July 20, 2018
Future of Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market including key players Abcam, BD, bioMerieux, Bio-Rad Laboratories
Enzyme-linked immunosorbent assay (ELISA) is mainly used to measure antibodies, antigens, proteins, and glycoproteins in biological samples. Posted via Industry Today. Follow us on Twitter @IndustryToday
June 25, 2018
Antibodies Global Market 2018: Key Players – Abcam PLC, Abnova, Active Motif, Agilent Technologies, BD Biosciences, Beckman Coulter Inc.
Antibodies -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
May 28, 2018
UPDATE 1-Brazil truckers association Abcam recommends end of strike
SAO PAULO, May 28 (Reuters) - A Brazilian truckers
association behind a week-long nationwide fuel-price protest
that paralyzed key sectors of Latin America's biggest economy
told drivers to get back to work on Monday after the government
caved in to their demands.
April 10, 2018
Protein Assays Market 10.8% of CAGR Expected by 2023 with Abcam plc, Lucigen Co, QIAGEN, Illumina Inc, Takara Bio Inc
Protein Assays Market Research Report– by Type (Copper-Ion-Based Assays, Test Strip-Based Assays, and Dye-Binding Assays), By Application (Diagnosis, Drug Discovery, and Protein Purification), By Product, By Technology, and By End User– Global forecast till 2023 Posted via Industry Today. Follow us …
January 17, 2018
Monoclonal Antibody Custom Service Market Accruals of Tremendous Growth by 2023 At 10.84% of CAGR
Monoclonal Antibody Custom Service Market provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information
Abcam Company Life and Culture
Report incorrect company information